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438 Y.-J. Tung et al.disease. Previous mycobacterial pulmonary disease (34.9%) was the most common underlying
disorder. Chest radiography indicated that bronchiectasis was common (47.2%) and that cavi-
tations were less common (14.2%). Fifty-six patients received antibiotic treatment. Clinicians
were more likely to prescribe antibiotics if the initial sputum acid-fast staining was positive
(p < 0.001). Treatment outcome was analyzed in 26 patients who were treated for more than
3 months; three of these patients (11.5%) had clinical failure and 18 (69.2%) experienced
sputum conversion. Patients with cavitary lesions were more likely to experience microbiologic
failure (pZ 0.02). Nine patients had positive cultures after antibiotic treatment for > 1 year.
Previous mycobacterial pulmonary disease (pZ 0.011) and cavitary lesion (pZ 0.034) are risk
factors for persistence of M. abscessus complex.
Conclusion: With antimicrobial therapy, previous mycobacterial disease, and cavitary lesion
are associated with microbiologic failure in Taiwanese adults with M. abscessus complex pul-
monary disease.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Nontuberculous mycobacteria (NTM) are environmental
pathogens that are a focus of recent concern because of the
increasing trend of NTM pulmonary infections.1e5 In Taiwan,
the proportion of NTM isolations among all mycobacterial
isolations increased from 32.3% in 2000 to 49.8% in 2008.3
Although the reasons for this increase are not entirely
clear, it is probably related to the increased number of
patients who are immunocompromised, increased preva-
lence of chronic lung diseases, increased numbers of the
elderly patients, and improved methods of detection.3,5e9
The Mycobacterium abscessus complex belongs to the
group of rapidly growing NTM (RGM).2,10 This species causes
a wide range of clinical infectious diseases that range from
localized cutaneous infection to disseminated disease.10e12
A previous study reported a nosocomial outbreak of pseu-
doinfection by this species from an infected endoscope
washer,13 and another study reported a cluster of endoph-
thalmitis caused by M. abscessus after cataract surgery.14
The pulmonary system is the most common site of infec-
tion, although empyema resulting from NTM is rare
compared with that from tuberculosis.15 The M. abscessus
complex accounts for over 80% of RGM chronic respiratory
diseases16 and is the second most common pulmonary NTM
infections in South Korea.17 The M. abscessus complex is
the most common cause of pulmonary NTM infections in
southern Taiwan,18 and the second most common cause in
northern Taiwan.3
Earlier studies divided the M. abscessus complex
(M. abscessus sensu lato) into three closely related species,
namely, M. abscessus subsp. abscessus (sensu stricto),
Mycobacterium massiliense, and Mycobacterium bolle-
tii.19,20 However, recent research proposed that M. massi-
liense and M. bolletii should be reclassified as M. abscessus
subsp. bolletii.21
Treatment of NTM infections is difficult because of their
resistance to most antibiotics. In particular, few drugs have
in vitro activity against the M. abscessus complex, and the
reported susceptibilities were 83e99% for clarithromycin,
95e97% for amikacin, 11e99% for cefoxitin, 8e55% forimipenem, 10e57% for ciprofloxacin, and 22.5e73% for
moxifloxacin.22e24 A recent study reported that the in vitro
susceptibility of NTM to tigecycline was 86e100%.25 The
American Thoracic Society (ATS) recommends treatment
with a combination of intravenous antibiotics (amikacin,
cefoxitin, or imipenem) and oral antibiotics (macrolide)
and/or surgery.2 Recent studies of patients with NTM in-
fections reported that those who received surgery in com-
bination with multiple medications26 and those infected by
M. massiliense had more favorable outcomes.27
Studies in Western countries indicated that most pa-
tients with RGM lung diseases were white, female, non-
smokers, older than 60 years, and had no predisposing
conditions or previously recognized lung diseases.2 To date,
there have been only a few reports on diseases caused by
the M. abscessus complex in Taiwan and risk factors related
to treatment outcome.25,28 In this study, we analyzed the
demographic characteristics and treatment outcomes of
patients with M. abscessus complex pulmonary diseases in a
Taiwan medical center.Methods
Patients
We retrospectively reviewed the medical charts of all pa-
tients who had positive cultures of respiratory specimens
(sputum or bronchial washing) for M. abscessus complex
and who visited or were admitted to the Kaohsiung Medical
University Hospital, a 1600-bed medical center in southern
Taiwan, from 2006 to 2012. Diagnosis of M. abscessus pul-
monary disease was based on the 2007 ATS criteria.2 Pa-
tients were followed up until December 2013. We recorded
all clinical symptoms, underlying diseases, laboratory data,
chest radiography results, and use of medications. Previous
mycobacterial disease was defined by the diagnosis of a
mycobacterial pulmonary infection (including tuberculosis
and NTM) 1 year before the isolation of the first positive
culture of M. abscessus. The other isolated NTMs were
defined by the presence of at least one NTM-positive
M. abscessus complex pulmonary disease in Taiwan 439culture, with isolation of a species other than Mycobacte-
rium avium complex (MAC) or M. abscessus complex. This
study was approved by the hospital’s Ethical Review Board
(KMUH-IRB-20110287).
Identification of M. abscessus complex
Sputum or bronchial washing specimens were sent to a
regional mycobacteriology reference laboratory for acid-
fast bacilli (AFB) smears and culturing. AFB smears were
performed initially with the fluorochrome method, and
the results were confirmed by the ZiehleNeelsen method.
Prior to 2008, specimens were inoculated into the Lo¨w-
ensteineJensen (LeJ) medium; since 2009, specimens were
inoculated into LeJ medium and grown in the BACTEC MGIT
960 liquid culture system (Becton, Dickinson and Company,
Franklin Lakes, NJ, USA). Colonies were identified using
polymerase chain reaction-restriction length polymorphism
analysis.29 Molecular identification of species within the M.
abscessus complex was not performed.
Radiologic findings
Chest radiographs [including initial and follow-up
chest X-rays, and chest high-resolution computed to-
mography (CT) data] were reviewed by an experienced
chest medicine specialist (J.-R.T.). The radiography pat-
terns were categorized according to the presence of
bronchiectasis, consolidations, cavities, and nodules. The
high-resolution CT findings were classified according to
the presence of bronchiectasis with nodules, cavities, and
consolidations.
Treatment and outcome
A macrolide-based regimen was defined as a regimen that
included a macrolide. When treatment duration was <
3 months or when clinicians stopped treatment after a
positive culture for M. abscessus complex, the clinical and
microbiologic outcomes were not analyzed. Outcome
measurements were recorded at the end of the 12th month
after treatment onset or at the end of the study. Sputum
conversion was defined by the presence of three consecu-
tive negative cultures within 6 months. The time of con-
version was defined as the date of the first negative
culture. If the patient could not expectorate sputum during
treatment, the sputum was classified as converted. Micro-
biologic failure of sputum conversion was defined by the
presence of positive cultures throughout the whole course
of follow up. Sputum relapse was defined by the presence
of two consecutive positive cultures after sputum conver-
sion.30 We also determined the rates of initial sputum
conversion (rate of sputum conversion from positivity to
negativity during treatment) and final sputum conversion
(rate of sputum conversion at the end of the study).
Clinical outcome was classified as success, improve-
ment, failure, or default.31 Clinical success was defined by
the presence of all of the following: (1) disappearance or
amelioration of clinical symptoms; (2) improvement or no
change in radiographic findings; (3) sputum conversion; and
(4) completion of treatment according to the physician’sjudgment. Clinical improvement was defined by the pres-
ence of amelioration of symptoms and/or signs, no evi-
dence of deterioration based on radiology results, and no
sputum conversion. Clinical failure was defined by the
presence of persistent symptoms and/or signs, deteriora-
tion based on radiology results, and positive sputum cul-
tures. The default was defined by the presence of any of
the following before the completion of treatment: (1) lost
to follow up, (2) death, or (3) self-stopping of medication or
missing medication two consecutive times.
Statistical analysis
All statistical calculations were performed with SPSS
version 19.0 (SPSS Inc., Chicago, IL, USA). Continuous data
were reported as means  standard deviations. Pearson’s
c2 test, Fisher’s exact test, the t test, and multivariate
logistic regression were used to analyze statistical corre-
lations. A p value < 0.05 was considered significant.
Results
Patient characteristics
During the study period, 390 patients had at least one
positive respiratory culture for M. abscessus complex, and
106 of these patients met the ATS criteria for NTM pulmo-
nary infection (Fig. 1). One hundred and sixty-three pa-
tients were excluded because of the presence of only one
positive culture, and the other 121 patients were excluded
for various other reasons.
Table 1 shows the demographic and clinical character-
istics of the 106 patients. The average age of the patients
was 64.56  14.11 years; 58.5% of the patients were female
and 79.2% of the patients were nonsmokers. Ninety-seven
patients (91.5%) had at least one underlying disorder and
63 patients (59.4%) had pre-existing lung diseases. Previous
mycobacterial infection was the most common underlying
disorder (34.9%), and 28 patients (26.4%) had histories of
pulmonary tuberculosis. None of the patients had cystic
fibrosis. Cough was the most common symptom (96.2%).
Fig. 2 shows the number of isolates, colonizations, and
infections caused by respiratory M. abscessus complex from
2006 to 2012. There was no obvious change in the annual
incidence of infection, but the colonization rates increased
significantly from 0.38/100,000 inpatients and outpatients
in 2006 to 4.24/100,000 inpatients and outpatients in 2012.
The timing of this increase corresponds to the introduction
of the BACTEC MGIT 960 liquid culture system in our
institution.
Radiographic findings
Table 2 summarizes the abnormalities observed in the
radiographic chest examinations. Most lesions were bilateral
(54.7%) and the right upper lung field was the most
frequently affected region (55.7%). The most frequent
pattern was bronchiectasis (50/106, 47.2%). The presence of
a cavitary lesionwas significantly associatedwith a history of
tuberculosis (8/28 vs. 7/78, pZ 0.023) and previous myco-
bacterial pulmonary disease (10/37 vs. 5/69, p Z 0.008).
Figure 1. Patient identification flow diagram. Mycobacterium abscessus complex. ATS Z American Thoracic Society.
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infection by M. abscessus complex. Forty-seven patients
(44.3%) received CT examinations, and the most common
finding was bronchiectasis with nodules (45/47, 95.7%).
Treatment and outcome
Fifty-six patients received antibiotic treatment and 50 pa-
tients did not receive treatment (Fig. 1 and Table 1).
Significantly more patients with initial sputum AFB posi-
tivity were given antibiotics than those with initial sputum
AFB negativity (39/56, 69.6% vs. 8/50, 16%; p < 0.001). In
addition, there were trends for antibiotic treatment to be
given to patients with previous mycobacterial disease (24/
56 vs. 13/50, pZ 0.102), previously isolated other NTM in a
pulmonary specimen (12/56 vs. 4/50, p Z 0.062), fever at
initial diagnosis (17/56 vs. 8/50, p Z 0.109), and cavitary
lesion (11/56 vs. 4/50, p Z 0.101), although these differ-
ences were not statistically significant. A higher acid-fast
smear (AFS) staining (from 3 þ to 4þ) result was alsoassociated with prescription of antibiotics (16/56, 28.6% vs.
4/50, 8.0%; p Z 0.012). Multivariate analysis with adjust-
ment for age and sex indicated that only initial AFS posi-
tivity was independently and significantly associated with
prescription of antibiotics (odds ratio, 10.75; 95% confi-
dence interval, 4.1e28.17; p < 0.001).
Forty-seven of 50 patients who did not receive treat-
ment had follow-up clinical symptoms, and 20 of these 47
patients (42.5%) experienced an amelioration of symptoms.
Thirty-six of the 47 patients had chest radiography follow
ups; the results indicated deterioration in 15 patients
(41.7%), improvement in five patients (13.9%), and no
change in 16 patients (44.4%).
Only 31 of the 56 treated patients (55.4%) received
treatment for> 3months, and five of these 31 patients were
lost to follow up (Fig. 1). Thus, we analyzed the clinical and
microbiologic outcomes of 26 cases (Table 3). Fifteen cases
(57.7%) were clinical successes, three cases (11.5%) had
clinical improvements, three cases (11.5%) were clinical
failures, and five cases (19.2%) achieved default. The initial
Table 1 Baseline characteristics of the 106 patients who met the criteria of the American Thoracic Society for pulmonary
infection caused by Mycobacterium abscessus complex
Characteristic All patients (N Z 106) Treated patients (N Z 56) Untreated patients (N Z 50) p (treated vs.
untreated)
Age at the time of
diagnosis, y
64.76  14.05
(27e95)
64.3  13.38
(27e95)
65.26  14.88
(27e92)
0.729
Female 62 (58.5) 34 (60.7) 28 (56) 0.695
BMI 21.29  4.35
(13.85e39.35)
21.19  4.22
(15.48e39.35)
21.41  4.56
(13.85e34.43)
0.795
Cigarette smoking
Never smoked 84 (79.2) 45 (80.4) 39 (78) 0.814
Immunosuppressive
therapy within 1 moa
8 (7.5) 6 (10.7) 2 (16) 0.277
Underlying disorders 97 (91.5) 53 (94.6) 44 (88) 0.301
Pre-existing pulmonary
diseases
63 (59.4) 32 (57.1) 31 (62) 0.693
Previous mycobacterial
pulmonary diseaseb
37 (34.9) 24 (42.9) 13 (26) 0.102
Previous history of
pulmonary
tuberculosis
28 (26.4) 17 (30.4) 11 (22) 0.382
Previous history of MAC 2 (1.9) 2 (3.6) 0 (0) 0.497
Other NTMs isolatedc 16 (15.1) 12 (21.4) 4 (8) 0.062
Bronchiectasis 29 (27.4) 13 (23.2) 16 (32) 0.384
GERD 22 (20.8) 12 (21.4) 10 (20) 0.999
Diabetes mellitus 10 (9.4) 4 (7.1) 6 (12) 0.511
Cirrhosis 5 (4.7) 2 (3.6) 3 (6) 0.665
Malignancies 14 (13.2) 8 (14.3) 6 (12) 0.781
HIV infection 2 (1.9) 2 (3.6) 0 (0) 0.497
Initial AFS positive 47 (44.3) 39 (69.6) 8 (16) <0.001
AFS 3 þ to 4þ 20 (18.9) 16 (28.6) 4 (8.0) 0.012
Cough 102 (96.2) 55 (98.2) 47 (94) 0.341
Hemoptysis 41 (38.7) 24 (42.9) 17 (34) 0.425
Feverd 25 (23.6) 17 (30.4) 8 (16) 0.109
Dyspnea 63 (59.4) 32 (57.1) 31 (62) 0.693
Death 15 (14.2) 7 (12.5) 8 (16) 0.781
a Steroid or chemotherapy or target therapy.
b Diagnosed mycobacterial infection (including tuberculosis and NTM) 1 year prior to the first positive cultures of Mycobacterium
abscessus being isolated.
c At least one NTM culture was isolated except for the Mycobacterium avium complex and M. abscessus complex.
d Body temperature above 38C at initial diagnosis.
Data are presented as n (%), mean  SD, or mean þ SD (range).
AFS Z acid-fast smear; BMI Z body mass index; GERD Z gastroesophageal reflux disease; HIV Z human immunodeficiency virus;
MAC Z Mycobacterium avium complex, NTM Z nontuberculous mycobacteria.
M. abscessus complex pulmonary disease in Taiwan 441sputum conversion rate was 73.1%. Three patients had
sputum relapse, but two of these patients ultimately had
sputum conversion. Thus, the final sputum conversion rate
was 69.2%. There were no differences in the rate of clinical
failure in patients who received a macrolide-based regimen,
a macrolideequinolone regimen, and an intravenous drug
regimen (Table 3). There were trends for an association of
history of tuberculosis with failure of sputumconversion (4/8
vs. 3/18, p Z 0.149) and clinical failure (2/3 vs. 5/23,
p Z 0.167), but the differences were not statistically sig-
nificant. The presence of cavitary lesions was significantly
associated with microbiologic failure (sputum conversion:
4/8; no sputum conversion: 1/18, pZ 0.02).
Analysis of microbiologic outcome at 1 year after
treatment for these 26 patients indicated that ninepatients had positive cultures and 17 patients had negative
cultures for M. abscessus complex (Table 4). Pre-existing
mycobacterial infection (8/9 vs. 5/17, p Z 0.03) and
cavitary lesion (4/9 vs. 1/17, p Z 0.02) were associated
with microbiologic failure. In addition, previous mycobac-
terial disease was associated with cavitary lesions (10/37
vs. 5/69, p Z 0.008), bilateral pulmonary lesions (26/37
vs. 32/69, p Z 0.024), and multiple-lobe lesions (13/37 vs.
9/69, p Z 0.011).
Mortality
Among the 106 patients who met the ATS criteria for pul-
monary M. abscessus complex infection, 15 patients died
(14.1%). This included nine of the 50 patients (18%) in the
Figure 2. Annual incidence of the number of isolates, colonizations, and infections by respiratory Mycobacterium abscessus
complex.
442 Y.-J. Tung et al.no-treatment group and six of the 56 patients (10.7%) in the
treatment group. None of the deaths was attributable to
the M. abscessus complex pulmonary disease.
Discussion
In our study population, only 27.1% (106/390) of patients
with one or more pulmonary isolates of M. abscessus com-
plex met the ATS criteria for diagnosis of NTM lung disease.
This result is comparable with that of a previous study in
North Taiwan, where the infection rate was 23.6%.32 By
contrast, Huang et al25 reported that 45% (18/40) of M.
abscessus complex isolates from patients at Taichung Vet-
erans General Hospital (from January 2006 to December
2008) were colonization isolates. The number of M.
abscessus isolates increased at our hospital from 2006 to
2012, but this increase was most likely due to the intro-
duction of the additional use of the BACTEC MGIT 960 liquid
culture system in 2009. The isolation of NTM has increased
worldwide, but the clinical significance of this increase
needs careful evaluation.
The patients in our study were mainly elderly females
and nonsmokers, as in the populations of patients with NTM
infections in Western countries.26 Most of our cases (91.5%)Table 2 Results of chest radiography of 106 patients with
pulmonary Mycobacterium abscessus complex infections
n (%) n (%)
Location Pattern
Right upper lobe 59 (55.7) Bronchiectasis 50 (47.2)
Left upper lobe 37 (34.9) Cavity 15 (14.2)
Right lower lobe 54 (51.9) Consolidation 21 (19.8)
Left lower lobe 49 (46.2) Nodular 19 (17.9)
Bilateral lesions 58 (54.7)
Multiple lobes ( 3) 22 (20.8)had at least one underlying disorder. A 1993 study of a
Western population showed that a specific underlying dis-
ease was rare in patients with RGM infections,16 but it is
increasingly reported that NTM disease occurs in patients
with underlying disorders, especially lung disease.1,4,7,26,33
The rate of previous mycobacterial diseases was high
among M. abscessus complex cases in the current study
(34.6%), as in Korea (53.1e61%).27,31 A study in the United
States reported that the rate of previous or coexisting MAC
in M. abscessus complex pulmonary disease was 55.1%.26
There appears to be differences among countries in the
occurrence of previous tuberculosis in patients with M.
abscessus complex pulmonary disease. In particular, the
occurrence of previous pulmonary tuberculosis in patients
with M. abscessus complex pulmonary disease was only
8.5e10% in the United States,16,26 11% in The
Netherlands,33 and 18% in France.7 However, the rate is
higher in southern Taiwan (26.9% in the current study and
56.7% in a previous study18), central Taiwan (31.8%),25 and
Korea (53.1%).27 In addition, none of our patients had cystic
fibrosis, although 6% of patients from the United States16
and 44% of patients from The Netherlands33 had this dis-
ease. The higher prevalence of tuberculosis and the lower
prevalence of cystic fibrosis in Taiwan may contribute to
the differences in susceptibility to M. abscessus complex
pulmonary infection in Taiwan and Western countries.
The radiographic characteristics of our patients were
variable. Cavitations were present in 13.5% of patients, but
were present in 15e44%, 17%, 6.2%, and 16e29.3% of pa-
tients in the United States,2,26 The Netherlands,33 France,7
and Korea,27,30,31 respectively. The relatively low rate of
lung cavitations and the association of this condition with
previous mycobacterial disease make this radiographic
finding a limited utility for the diagnosis of M. abscessus
complex lung diseases.
According to the ATS guidelines, a diagnosis of NTM lung
disease does not necessarily require therapy, and initiation
of therapy is based on potential risks and benefits.2 A
Table 3 Clinical outcome of 26 treated patients for whom clinical and microbiologic outcomes were available
Characteristic Total (N Z 26) Success (N Z 15) Improvement (N Z 3) Failure (N Z 3) Default (N Z 5)
Age, y 59.23  14.25 60.21  17.04 60.42  10.38 59.11  1.24 55.66  13.37
Female 20 (76.95) 11 (73.33) 3 (100) 3 (100) 3 (60)
Duration (mo) 13.2  13.19 15.1  12.27 9.83  4.75 10.5  5.41 11.1  4.9
Medication
Macrolidea 19 (73.07) 10 (52.6) 2 (10.5) 2 (10.5) 5 (26.3)
Macrolide þ quinoloneb 14 (53.8) 7 (50) 2 (14.2) 2 (14.2) 3 (21.4)
Intravenous medicinec 3 (11.5) 1 (33.3) 0 (0) 1 (33.3) 1 (33.3)
HERZd 7 (26.9) 5 (71.4) 1 (14.3) 1 (14.3) 0 (0)
a All 19 cases received clarithromycin; two cases also have been receiving azithromycin.
b Nine cases received clarithromycin with moxifloxacin; five cases received clarithromycin with ciprofloxacin.
c All three cases received amikacin; one case also received meropenem and another received imipenem/cilastatin.
d Isoniazid, ethambutol, rifampin, and pyrazinamide.
Data are presented as n (%) or mean  SD.
M. abscessus complex pulmonary disease in Taiwan 443Korean retrospective study reported that female patients
who were younger had more respiratory symptoms and
positive sputum AFB smears, and cavitations on chest
radiography were more likely to be treated, with an initial
strategy of observation for 6e12 months after M. abscessus
complex pulmonary disease diagnosis.30 By contrast, our
multivariate analysis indicated that only initial sputum AFS
positivity was significantly associated with the decision to
prescribe an antibiotic.
For our 56 patients who received treatment, clinical
symptoms were ameliorated in 76.9% of patients and the
final sputum conversion rate was 69.2%. This conversion
rate is higher than reported in previous studies in Korea
(58%)26 and the United States (48%).30 As in previous studiesTable 4 Microbiologic outcome at 1 year after treatment
in the 26 treated patients for whom clinical and microbio-
logic outcomes were available
Characteristic No sputum
conversion
(N Z 9)
Sputum
conversion
(N Z 17)
p
Age, y 56.2  9.9 60.8  16.15 0.449
Female 7 (77.8) 13 (76.5) >0.999
Pre-existing lung disease 8 (88.9) 9 (52.9) 0.098
Previous mycobacterial
disease
8 (88.9) 5 (29.4) 0.011
Previous tuberculosis 3 (33.3) 4 (23.5) 0.661
Cavitary lesion 4 (44.4) 1 (5.9) 0.034
Medication
Macrolidea 7 (77.8) 12 (70.6) >0.999
Intravenous medicationb 2 (22.2) 1 (5.9) 0.268
Macrolide þ quinolonec 7 (77.8) 7 (41.2) 0.11
HERZd 2 (22.2) 5 (29.4) >0.999
a All 19 cases received clarithromycin; two cases also have
been receiving azithromycin.
b Nine cases received clarithromycin with moxifloxacin; five
cases received clarithromycin with ciprofloxacin.
c All three cases received amikacin; one case also received
meropenem and another received imipenem/cilastatin.
d Isoniazid, ethambutol, rifampin, and pyrazinamide.
Data are presented as n (%) or mean  SD.of M. abscessus complex pulmonary disease, we found that
microbiological clearance was more difficult than amelio-
ration of clinical symptoms.
There is no specific regimen of choice for treatment of
M. abscessus complex pulmonary disease. Multidrug regi-
mens that include a macrolide may cause symptomatic
improvement and disease regression.2,30 We found no sig-
nificant difference in clinical outcome of those treated with
a macrolide-based regimen and those treated with a non-
macrolide regimen. The nonmacrolide regimens in our
study were first-line medications for pulmonary tubercu-
losis, and had no in vitro effects on M. abscessus complex.
However, only one patient (14.3%) experienced clinical
failure. van Ingen et al33 also reported that five patients
with M. abscessus complex pulmonary disease received
ineffective regimens, although all were cured. Thus, they
questioned the current ATS guidelines regarding the over-
diagnosis of NTM pulmonary diseases. In our group of un-
treated patients, 42.6% experienced amelioration of
symptoms, and only 44.4% had radiographic evidence of
deterioration. Thus, it is uncertain whether the observed
clinical success of treated patients can be explained by the
use of antibiotics or the natural course of NTM pulmonary
disease.
A study in northern Taiwan showed that Mycobacterium
chelonae-abscessus pulmonary disease initially has under-
lying comorbidity, structural lung disease, and sputum AFS
positivity as risk factors for persistent M. chelonae-
abscessus pulmonary disease and is associated with radio-
graphic deterioration.28 Our study showed that the pres-
ence of a cavitary lesion and the occurrence of previous
mycobacterial pulmonary disease were associated with
poor microbiologic outcome. The presence of previous
mycobacterial disease was associated with the presence of
bilateral lesions, multiple-lobe lesions, and cavitary le-
sions, and resulted in structural lung disease. Thus, pa-
tients with previous or underlying mycobacterial infection
and cavitary lesion may require prolonged or more aggres-
sive treatment to achieve sputum conversion.
Recent studies have also focused on expression of the
erm gene and inducible resistance to clarithromycin in
M. abscessus and M. massiliense.34 Previous studies on M.
massiliense infections in Korea and Japan reported better
444 Y.-J. Tung et al.clinical outcome and lower resistance to clarithromycin in
patients without the erm gene or with an inactive form of
this gene.27,35 A study in The Netherlands reported that
M. abscessus subsp. abscessus was more likely to cause true
NTM disease than M. abscessus subsp. bolletii and to have
high resistance to clarithromycin.33 Currently, there is a
tendency to identify species of M. abscessus complex in
clinically significant isolates in the world.
There are limitations in this study. First, as a retro-
spective study, the treatment regimens were diverse and
this made it difficult to compare the efficacy of different
regimens. The follow-up protocol also varied, and there-
fore, the precise time of sputum conversion was not
available. Second, we did not differentiate M. massiliense
from M. abscessus and perform antimicrobial susceptibility
testing, and therefore, we were not able to examine the
correlation of clinical response and in vitro results.
In conclusion, patients with M. abscessus complex pul-
monary disease were mainly elderly, female, nonsmokers,
and had pre-existing pulmonary diseases. Initial AFS posi-
tivity was associated with the administration of antibiotics
by clinicians. With antimicrobial therapy, previous myco-
bacterial disease and cavitary lesion were associated with
microbiologic failure in Taiwanese adults with M. abscessus
complex pulmonary disease.Conflicts of interest
All contributing authors declare no conflicts of interest.Acknowledgement
This study was supported by a grant from the Kaohsiung
Medical University Hospital (KMUH98-8G13).References
1. Field SK, Cowie RL. Lung disease due to the more common
nontuberculous mycobacteria. Chest 2006;129:1653e72.
2. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C,
Gordin F, et al. An official ATS/IDSA statement: diagnosis,
treatment, and prevention of nontuberculous mycobacterial
diseases. Am J Respir Crit Care Med 2007;175:367e416.
3. Lai CC, Tan CK, Chou CH, Hsu HL, Liao CH, Huang YT, et al.
Increasing incidence of nontuberculous mycobacteria, Taiwan,
2000e2008. Emerg Infect Dis 2010;16:294e6.
4. Marras TK, Daley CL. Epidemiology of human pulmonary
infection with nontuberculous mycobacteria. Clin Chest Med
2002;23:553e67.
5. Martı´n-Casabona N, Bahrmand AR, Bennedsen J, Thomsen VO,
Curcio M, Fauville-Dufaux M, et al. Non-tuberculous myco-
bacteria: patterns of isolation. A multi-country retrospective
survey. Int J Tuberc Lung Dis 2004;8:1186e93.
6. Chetchotisakd P, Kiertiburanakul S, Mootsikapun P,
Assanasen S, Chaiwarith R, Anunnatsiri S. Disseminated non-
tuberculous mycobacterial infection in patients who are not
infected with HIV in Thailand. Clin Infect Dis 2007;45:421e7.
7. Dailloux M, Abalain ML, Laurain C, Lebrun L, Loos-Ayav C,
Lozniewski A, et al. Respiratory infections associated with
nontuberculous mycobacteria in non-HIV patients. Eur Respir J
2006;28:1211e5.8. Miguez-Burbano MJ, Flores M, Ashkin D, Rodriguez A,
Granada AM, Quintero N, et al. Non-tuberculous mycobacteria
disease as a cause of hospitalization in HIV-infected subjects.
Int J Infect Dis 2006;10:47e55.
9. Saritsiri S, Udomsantisook N, Suankratay C. Nontuberculous
mycobacterial infections in King Chulalongkorn Memorial Hos-
pital. J Med Assoc Thai 2006;89:2035e46.
10. Brown-Elliott BA, Wallace Jr RJ. Clinical and taxonomic status
of pathogenic nonpigmented or late-pigmenting rapidly
growing mycobacteria. Clin Microbiol Rev 2002;15:716e46.
11. Su SH, Chen YH, Tsai TY, Huang SC, Lin CY, Chen TC, et al.
Catheter-related Mycobacterium abscessus bacteremia man-
ifested with skin nodules, pneumonia, and mediastinal
lymphadenopathy. Kaohsiung J Med Sci 2013;29:50e4.
12. Hsiao CH, Lai CC, Hsueh PR. High recurrence rate of lymphad-
enitis due to nontuberculous mycobacteria and its association
with concurrent Salmonella infection in Taiwan. J Microbiol
Immunol Infect 2014;47:217e21.
13. Maloney S, Welbel S, Daves B, Adams K, Becker S, Bland L,
et al. Mycobacterium abscessus pseudoinfection traced to an
automated endoscope washer: utility of epidemiologic and
laboratory investigation. J Infect Dis 1994;169:1166e9.
14. Hung JH, Huang YH, Chang TC, Tseng SH, Shih MH, Wu JJ, et al.
A cluster of endophthalmitis caused by Mycobacterium
abscessus after cataract surgery. J Microbiol Immunol Infect
2014. http://dx.doi.org/10.1016/j.jmii.2014.02.001.
15. Lai CC, Chao CM, Gau SJ, Hsueh PR. Thoracic empyema and
bacteremia due to Mycobacterium abscessus in a patient with
liver cirrhosis. J Microbiol Immunol Infect 2013;46:482e4.
16. Griffith DE, Girard WM, Wallace Jr RJ. Clinical features of
pulmonary disease caused by rapidly growing mycobacteria. An
analysis of 154 patients. Am Rev Respir Dis 1993;147:1271e8.
17. Simons S, van Ingen J, Hsueh PR, Van Hung N, Dekhuijzen PN,
Boeree MJ, et al. Nontuberculous mycobacteria in respiratory
tract infections, eastern Asia. Emerg Infect Dis 2011;17:
343e9.
18. Wang CC, Lin MC, Liu JW, Wang YH. Nontuberculous myco-
bacterial lung disease in southern Taiwan. Chang Gung Med J
2009;32:499e508.
19. Ade´kambi T, Berger P, Raoult D, Drancourt M. rpoB gene
sequence-based characterization of emerging non-tuberculous
mycobacteria with descriptions of Mycobacterium bolletii sp.
nov., Mycobacterium phocaicum sp. nov. and Mycobacterium
aubagnense sp. nov. Int J Syst Evol Microbiol 2006;56:133e43.
20. Ade´kambi T, Reynaud-Gaubert M, Greub G, Gevaudan MJ, La
Scola B, Raoult D, et al. Amoebal coculture of “Mycobacterium
massiliense” sp. nov. from the sputum of a patient with
hemoptoic pneumonia. J Clin Microbiol 2004;42:5493e501.
21. Leao SC, Tortoli E, Euze´by JP, Garcia MJ. Proposal that Myco-
bacterium massiliense and Mycobacterium bolletii be united
and reclassified as Mycobacterium abscessus subsp. bolletii
comb. nov., designation of Mycobacterium abscessus subsp.
abscessus subsp. nov. and emended description of Mycobac-
terium abscessus. Int J Syst Evol Microbiol 2011;61:2311e3.
22. Park S, Kim S, Park EM, Kim H, Kwon OJ, Chang CL, et al.
In vitro antimicrobial susceptibility of Mycobacterium absces-
sus in Korea. J Korean Med Sci 2008;23:49e52.
23. Miyasaka T, Kunishima H, Komatsu M, Tamai K, Mitsutake K,
Kanemitsu K, et al. In vitro efficacy of imipenem in combina-
tion with six antimicrobial agents against Mycobacterium
abscessus. Int J Antimicrob Agents 2007;30:255e8.
24. Lee SM, Jm Kim, Jeong J, Park YK, Bai GH, Lee EY, et al.
Evaluation of the broth microdilution method using 2,3-
diphenyl-5-thienyl-(2)-tetrazolium chloride for rapidly
growing mycobacteria susceptibility testing. J Korean Med Sci
2007;22:784e90.
25. Huang YC, Liu MF, Shen GH, Lin CF, Kao CC, Liu PY, et al.
Clinical outcome of Mycobacterium abscessus infection and
M. abscessus complex pulmonary disease in Taiwan 445antimicrobial susceptibility testing. J Microbiol Immunol Infect
2010;43:401e6.
26. Jarand J, Levin A, Zhang L, Huitt G, Mitchell JD, Daley CL.
Clinical and microbiologic outcomes in patients receiving
treatment for Mycobacterium abscessus pulmonary disease.
Clin Infect Dis 2011;52:565e71.
27. Koh WJ, Jeon K, Lee NY, Kim BJ, Kook YH, Lee SH, et al.
Clinical significance of differentiation of Mycobacterium mas-
siliense from Mycobacterium abscessus. Am J Respir Crit Care
Med 2011;183:405e10.
28. Lee MR, Keng LT, Shu CC, Lee SW, Lee CH, Wang JY, et al. Risk
factors for Mycobacterium chelonae-abscessus pulmonary dis-
ease persistence and deterioration. J Infect 2012;64:228e30.
29. Anon. Diagnostic Standards and Classification of Tuberculosis in
Adults and Children. This official statement of the American
Thoracic Society and the Centers for Disease Control and Pre-
vention was adopted by the ATS Board of Directors, July 1999.
This statement was endorsed by the Council of the Infectious
Disease Society of America, September 1999. Am J Respir Crit
Care Med 2000;161:1376e95.
30. Jeon K, Kwon OJ, Lee NY, Kim BJ, Kook YH, Lee SH, et al.
Antibiotic treatment of Mycobacterium abscessus lung disease:a retrospective analysis of 65 patients. Am J Respir Crit Care
Med 2009;180:896e902.
31. Lyu J, Jang HJ, Song JW, Choi CM, Oh YM, Lee SD, et al. Out-
comes in patients with Mycobacterium abscessus pulmonary
disease treated with long-term injectable drugs. Respir Med
2011;105:781e7.
32. Lai CC, Wang HC. Clinical significance of Mycobacterium
abscessus isolates at a medical center in Northern Taiwan.
J Microbiol Immunol Infect 2011;44:488e9.
33. van Ingen J, de Zwaan R, Dekhuijzen RP, Boeree MJ, van
Soolingen D. Clinical relevance of Mycobacterium chelonae-
abscessus group isolation in 95 patients. J Infect 2009;59:
324e31.
34. Nash KA, Brown-Elliott BA, Wallace Jr RJ. A novel gene,
erm(41), confers inducible macrolide resistance to clinical
isolates of Mycobacterium abscessus but is absent from Myco-
bacterium chelonae. Antimicrobial Agents Chemother 2009;
53:1367e76.
35. Harada T, Akiyama Y, Kurashima A, Nagai H, Tsuyuguchi K,
Fujii T, et al. Clinical and microbiological differences between
Mycobacterium abscessus and Mycobacterium massiliense lung
diseases. J Clin Microbiol 2012;50:3556e61.
